Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL
The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).
Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out
Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to be a disastrous mistake, triggering three years of share price losses. Newly spun-out GRAIL faces challenges in the competitive cancer testing market, while Illumina returns to its profitable gene sequencing business.
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84.
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
GRAL Stock Alert: 7 Things to Know as Grail Starts Trading Today
The world of biotech stocks got a new member today. Grail (NASDAQ: GRAL ) has successfully completed its spinoff from industry leader Illumina (NASDAQ: ILMN ).
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.
Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's decision to spin off its blood testing company – Grail.
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock.
Genetics sequencing leader Illumina reported a strong start to 2024. Nike has been lagging the S&P 500 this year.
Illumina to spin off Grail in June
Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail.
